IV Iron Therapy Fails to Cut Heart Failure Deaths in Landmark FAIR-HF2 Trial
The FAIR-HF2 trial tested intravenous ferric carboxymaltose in iron-deficient heart failure patients, with surprising results for hard clinical endpoints.
Summary
FAIR-HF2 was a large randomized controlled trial testing whether intravenous ferric carboxymaltose (FCM) reduces hospitalizations and death in heart failure patients with iron deficiency. Despite earlier smaller trials suggesting quality-of-life benefits, FAIR-HF2 found no statistically significant reduction in the primary composite endpoint of cardiovascular death or worsening heart failure events compared to placebo. The trial enrolled patients across multiple European countries and was adequately powered. While iron levels improved in treated patients, this did not translate into meaningful reductions in hard clinical outcomes. These results add important nuance to the debate over routine IV iron supplementation in heart failure, suggesting symptom benefits may not extend to mortality and hospitalization reduction.
Detailed Summary
Iron deficiency affects approximately 50% of patients with heart failure and has been associated with reduced exercise capacity, worse quality of life, and poorer prognosis. Earlier trials, including the original FAIR-HF study, demonstrated that intravenous ferric carboxymaltose (FCM) improved symptoms and functional status, leading to guideline recommendations for its use. FAIR-HF2 was designed to determine whether these benefits translate into reductions in hard clinical endpoints such as cardiovascular death and worsening heart failure.
The FAIR-HF2 DZHK05 trial was a multicenter, randomized, double-blind, placebo-controlled trial conducted across Germany, Spain, Hungary, Poland, Slovenia, and other European sites. Patients with stable heart failure, reduced or mildly reduced ejection fraction, and confirmed iron deficiency (defined by serum ferritin <100 ng/mL or ferritin 100–299 ng/mL with transferrin saturation <20%) were enrolled and randomized to receive intravenous FCM or placebo at regular intervals. The primary composite endpoint was the total number of cardiovascular deaths and worsening heart failure events (hospitalizations and urgent outpatient visits), analyzed using a win ratio or recurrent events framework.
Despite successfully correcting iron deficiency parameters in the treatment arm, FAIR-HF2 did not demonstrate a statistically significant reduction in the primary composite endpoint. The rate of cardiovascular death and worsening heart failure events was numerically lower in the FCM group, but the difference did not reach statistical significance. This was a notable and somewhat unexpected finding given the biological plausibility of iron repletion benefiting cardiac function and the positive signal from prior smaller trials.
These results must be interpreted alongside contemporaneous trials such as AFFIRM-AHF and HEART-FID, which similarly failed to show significant reductions in hard endpoints with IV iron in heart failure. Collectively, these trials suggest that while FCM safely corrects iron deficiency and may improve patient-reported outcomes and exercise tolerance, the effect on cardiovascular death and hospitalization is at best modest and may not meet the bar of statistical significance in adequately powered trials. Meta-analytic approaches combining these trials may still reveal a small but real benefit.
For clinicians and patients, FAIR-HF2 raises important questions about the value of routine IV iron supplementation purely to reduce hospitalizations or mortality. However, symptom relief and quality-of-life improvements remain clinically meaningful, and iron deficiency correction may still be warranted in symptomatic patients. The trial underscores the importance of large, well-powered studies before broad adoption of therapies based on surrogate endpoint data.
Key Findings
- IV ferric carboxymaltose did not significantly reduce the composite of CV death or worsening heart failure versus placebo.
- Iron deficiency parameters improved in the FCM group, confirming successful iron repletion.
- Results align with AFFIRM-AHF and HEART-FID, which also failed to show significant hard endpoint reduction.
- Quality-of-life and symptomatic benefits from IV iron remain biologically plausible but were not the primary endpoint.
- The trial was adequately powered, making a large treatment effect on hard endpoints unlikely.
Methodology
FAIR-HF2 was a multicenter, randomized, double-blind, placebo-controlled trial enrolling iron-deficient heart failure patients across multiple European countries. The primary endpoint was a composite of cardiovascular death and worsening heart failure events, analyzed using recurrent event methodology. The trial was adequately powered based on prior event rate assumptions.
Study Limitations
The trial's null result on hard endpoints may reflect true absence of mortality/hospitalization benefit or insufficient follow-up duration. Population heterogeneity across sites and potential variability in iron deficiency definition may affect generalizability. Results may differ in acute decompensated heart failure or HFpEF populations not well-represented here.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.